Monoclonal antibodies (mAbs) have been a huge success story in the biopharmaceutical industry. With the acquisition of Just – Evotec Biologics in 2019, Evotec made a major push into biologics and has successfully built a fully-integrated platform to drive mAb programs from concept through commercialization.

Evotec offers a comprehensive repertoire of leading-edge, synergistic discovery technologies, such as in vivo, animal-derived B cells and in vitro, library-derived antibody display platforms. Through our extensive drug discovery know how, we can design customized research plans, applying the best suited antibody discovery platform and optimal screening and profiling tests – thereby always focusing on the target biology, disease setting and intended mode of action of the molecule. This holds true for standard IgG molecules, as well as more sophisticated formats, such as bispecific antibodies, or even antibody drug conjugates. 

Moreover, we are leveraging a range of powerful approaches to optimize the mAb discovery process. High-throughput screening protocols, artificial intelligence / machine learning tools and analytical support speeds up the development cycle, allowing for a precise selection of the desired mAb candidates and ultimately reducing the failures at advanced development stages.

Importantly, the antibody discovery services can be accessed as stand-alone services or through Evotec’s seamless integrated antibody drug discovery platform.

For state-of-the-art monoclonal antibody development, Evotec has established a unique one-stop-shop from target identification to IND. This includes our broad technology platform as well as unparalleled expertise in drug development and even manufacturing, including latest advances in artificial intelligence to create synthetic realistic outcomes by machine learning.

Our clients and collaboration partners can make use of our industry-leading, long-standing experience in a broad range of target classes, the breadth and depth of the extensive disease biology, the availability of biology relevant and mechanism-driven assays and models applied in a rational and efficient way. Evotec has in-depth disease expertise in anti-infectives, respiratory diseases, immunology, oncology, metabolic diseases and neurology. Depending on the therapeutic area and the target, Evotec employs relevant translational in vitro or ex vivo assays that assess desired functional effects of the candidate molecules. We develop suitable pharmacodynamic read-outs that either provide a target-proximal read-out, target engagement, or that quantify desired downstream effects. If available and desired, candidate molecules can also be tested in relevant disease models to assess efficacy in animal models.

Evotec’s preclinical department offers the full range of in vitro and in vivo GLP and non-GLP preclinical evaluation studies to thoroughly assess the safety profile of the drug candidate. Our clients and collaboration partners can benefit from our extensive understanding of PK/PD relationship for human dose prediction.

Finally, Evotec can perform Biomarker discovery and Biomarker studies to enable diagnosis, assessment of target engagement and pharmacodynamics effects, patient stratification or prediction of therapeutic success. In this context, Evotec offers a comprehensive proteomics and ligand binding assay platform to support Biomarker sciences from discovery through to the clinic.

All of this is supported by data-driven solutions to biologics design and manufacturing to ensure smooth transition into development and reduced risk of downstream attrition and delay.

This unparalleled infrastructure and translational expertise put Evotec in a unique position to conduct leading-edge, integrated monoclonal antibody development programs all the way from target identification to manufacturing.